Joanna M Poczobutt
Overview
Explore the profile of Joanna M Poczobutt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
470
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kleczko E, Poczobutt J, Navarro A, Laskowski J, Johnson A, Korpela S, et al.
Front Oncol
. 2023 Jan;
12:1045690.
PMID: 36686777
Introduction: , cancer cells respond to signals from the tumor microenvironment resulting in changes in expression of proteins that promote tumor progression and suppress anti-tumor immunity. This study employed an...
2.
Hume P, McClendon J, Kopf K, Harral J, Poczobutt J, McCubbrey A, et al.
Am J Physiol Lung Cell Mol Physiol
. 2022 Aug;
323(4):L391-L399.
PMID: 35943156
The pathogenesis of chronic obstructive pulmonary disease (COPD), a prevalent disease primarily caused by cigarette smoke exposure, is incompletely elucidated. Studies in humans and mice have suggested that hypoxia-inducible factor-1α...
3.
Poczobutt J, Mikosz A, Poirier C, Beatman E, Serban K, Gally F, et al.
Am J Respir Cell Mol Biol
. 2021 Mar;
64(5):629-640.
PMID: 33662226
Deficiency of ASM (acid sphingomyelinase) causes the lysosomal storage Niemann-Pick disease (NPD). Patients with NPD type B may develop progressive interstitial lung disease with frequent respiratory infections. Although several investigations...
4.
Johnson A, Bullock B, Neuwelt A, Poczobutt J, Kaspar R, Li H, et al.
J Immunol
. 2020 Mar;
204(8):2295-2307.
PMID: 32179637
MHC class II (MHCII) expression is usually restricted to APC but can be expressed by cancer cells. We examined the effect of cancer cell-specific MHCII (csMHCII) expression in lung adenocarcinoma...
5.
Bullock B, Kimball A, Poczobutt J, Neuwelt A, Li H, Johnson A, et al.
Life Sci Alliance
. 2019 May;
2(3).
PMID: 31133614
Targeting PD-1/PD-L1 is only effective in ∼20% of lung cancer patients, but determinants of this response are poorly defined. We previously observed differential responses of two murine K-Ras-mutant lung cancer...
6.
Sippel T, Johnson A, Li H, Hanson D, Nguyen T, Bullock B, et al.
Mol Cancer Res
. 2019 May;
17(8):1748-1758.
PMID: 31088909
Lung cancer is a heterogeneous disease in which patient-specific treatments are desirable and the development of targeted therapies has been effective. Although mutations in are frequent in lung adenocarcinoma, there...
7.
Poczobutt J, Eickelberg O
Am J Respir Crit Care Med
. 2019 Feb;
199(12):1454-1456.
PMID: 30715901
No abstract available.
8.
Li H, McSharry M, Walker D, Johnson A, Kwak J, Bullock B, et al.
Oncoimmunology
. 2018 May;
7(5):e1423182.
PMID: 29721380
Lung-specific overexpression of prostacyclin synthase (PGIS) decreases tumor initiation in murine lung cancer models. Prostacyclin analogs prevent lung tumor formation in mice and reverse bronchial dysplasia in former smokers. However,...
9.
Montford J, Lehman A, Bauer C, Klawitter J, Klawitter J, Poczobutt J, et al.
J Lipid Res
. 2017 Dec;
59(2):380-390.
PMID: 29229740
The group IVA calcium-dependent cytosolic phospholipase A2 (cPLA2α) enzyme directs a complex "eicosanoid storm" that accompanies the tissue response to injury. cPLA2α and its downstream eicosanoid mediators are also implicated...
10.
Kwak J, Laskowski J, Li H, McSharry M, Sippel T, Bullock B, et al.
Cancer Res
. 2017 Nov;
78(1):143-156.
PMID: 29118090
The complement cascade is a part of the innate immune system that acts primarily to remove pathogens and injured cells. However, complement activation is also peculiarly associated with tumor progression....